Marksans Pharma Limited

rs,

Date: August 12, 2025 BSE Limited Corporate Relation Department Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400001. Scrip Code: 524404 National Stock Exchange of India Limited List

5%

N D C E O “While Q1FY26 was a seasonally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in th

8.9%

ally soft quarter, we delivered year-on-year revenue growth of 5%, while gross profit increased by 8.9%. This was supported by successful new product launches in the US markets and the easing of raw mat

₹ 620

creating enduring value for our stakeholders in FY26 and beyond.” 6 2 Y F 1 Q Operating Revenue ₹ 620 cr EBITDA ₹ 100 cr EBITDA Margin 16.1% PAT ₹ 58 cr www.marksanspharma.com Page 5 Financial Hig

₹ 100

g value for our stakeholders in FY26 and beyond.” 6 2 Y F 1 Q Operating Revenue ₹ 620 cr EBITDA ₹ 100 cr EBITDA Margin 16.1% PAT ₹ 58 cr www.marksanspharma.com Page 5 Financial Highlights Q1FY26 –

16.1%

ders in FY26 and beyond.” 6 2 Y F 1 Q Operating Revenue ₹ 620 cr EBITDA ₹ 100 cr EBITDA Margin 16.1% PAT ₹ 58 cr www.marksanspharma.com Page 5 Financial Highlights Q1FY26 – YoY Performance Q1FY26

₹ 58

6 and beyond.” 6 2 Y F 1 Q Operating Revenue ₹ 620 cr EBITDA ₹ 100 cr EBITDA Margin 16.1% PAT ₹ 58 cr www.marksanspharma.com Page 5 Financial Highlights Q1FY26 – YoY Performance Q1FY26 Q1FY25 Y

₹ 620.0

ancial Highlights Q1FY26 – YoY Performance Q1FY26 Q1FY25 YoY Growth % YoY Performance Revenue ₹ 620.0 cr ₹ 590.6 cr 5.0% Gross Profit Gross Margin ₹ 358.2 cr 57.8% ₹ 328.8 cr 55.7% 8.9% EBITDA EB

₹ 590.6

ights Q1FY26 – YoY Performance Q1FY26 Q1FY25 YoY Growth % YoY Performance Revenue ₹ 620.0 cr ₹ 590.6 cr 5.0% Gross Profit Gross Margin ₹ 358.2 cr 57.8% ₹ 328.8 cr 55.7% 8.9% EBITDA EBITDA Margin

5.0%

– YoY Performance Q1FY26 Q1FY25 YoY Growth % YoY Performance Revenue ₹ 620.0 cr ₹ 590.6 cr 5.0% Gross Profit Gross Margin ₹ 358.2 cr 57.8% ₹ 328.8 cr 55.7% 8.9% EBITDA EBITDA Margin ₹ 100.1

₹ 358.2

5 YoY Growth % YoY Performance Revenue ₹ 620.0 cr ₹ 590.6 cr 5.0% Gross Profit Gross Margin ₹ 358.2 cr 57.8% ₹ 328.8 cr 55.7% 8.9% EBITDA EBITDA Margin ₹ 100.1 cr 16.1% ₹ 128.4 cr 21.7% 22.0% N

57.8%

th % YoY Performance Revenue ₹ 620.0 cr ₹ 590.6 cr 5.0% Gross Profit Gross Margin ₹ 358.2 cr 57.8% ₹ 328.8 cr 55.7% 8.9% EBITDA EBITDA Margin ₹ 100.1 cr 16.1% ₹ 128.4 cr 21.7% 22.0% Net Profi

“• Relonchem has more than 160+ Market Authorizations • In FY25, Approved 12 products | Filed 18 products during the year www.marksanspharma.com Page 12 Australia & New Zealand Q1FY26 Performance Quarterly Performance (₹ cr) 9.2% 66 64 47 77 57 13.1% YoY 25.5% QoQ Australia & New Zealand Overview Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Revenue ₹ 57.0 cr Highlights • Strong Q4 led to a softer Q1, which is in line with typical business trends.”

“• Despite Q1 seeing a year-over-year decline, we do not anticipate full-year degrowth.”

“ACC RED ITATI ONS Unit 2 in Goa Acquired Manufacturing facility in Goa • Scalable capacity with a plan to double the existing Indian capacity from 8bn units per annum • Manufacturing site is spread across 47,597 sq.”

“• Plan to manufacture tablets, ointments, liquids and creams ACC RED ITATI ONS www.marksanspharma.com *Acquired facility in Goa has scalable capacity to 8bn units p.a.”

“SKUs growth of ~75% to 1500+ Note: All numbers as of FY25 *Acquired facility in Goa has scalable capacity to 8bn units p.a.”

“Aim to capture a significant part of the multi-billion-dollar OTC opportunity.”

“• Our OTC segment grew at CAGR of 21% (from FY17-FY25) • Marksans is the most preferred and growing low-cost store brand manufacturing partner Innovation & Pipeline Power • Continued focus on R&D leading to a strong product pipeline and successful launches • Strong pipeline of more than 100 products Scale capacity and operating leverage • Aim to expanding capacity , scale the acquired unit in Goa, capacity to 8bn units p.a.”

“Evaluating acquisitions in Europe region for front-end presence www.marksanspharma.com Page 32 We’ve Delivered What We Promised S.no Marksans Guidance How have we performed?”

“01 Revenue guidance of ₹ 2,000 cr Achieved 02 Focus on expanding OTC business – ~4.6x revenue growth since 2017 Achieved 03 Disciplined capital allocation approach - Effectively utilizing the cash through buyback, dividends, targeted acquisitions and capacity expansion Achieved www.marksanspharma.com Page 33 Growth: FY26 and Beyond Disciplined efforts to become future ready Strategic Roadmap • Doubling low-cost manufacturing capacity in India from • High growth in revenues and margin.”

Primary drivers of margin movement were

1

Primarily driven by

1

Product Approvals

1

Total Capacity

1

For more information please contact

1

Primary drivers of margin movement were

1) Higher employee costs due to new hires at the acquired facility 2) One-time Expected Credit Loss (ECL) provision for the Emerging Market Division - ₹10.48 Cr 3) Lack of operating leverage amid softer demand. Demand has started improving in Q2 • Largely attributable to the EBITDA impact and a mark-to-market forex loss of ₹6.2 Cr. Finance costs increased due to higher lease rentals. www.marksanspharma.com Note: Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income) Page 6 Financial Highlights Q1FY26 – QoQ Performance Q1FY26 Q4FY25 QoQ Growth % QoQ Performance Revenue ₹ 620.0 cr ₹ 708.5 cr 12.5% • Softer demand due to seasonal headwinds. Q2 has already started showing signs of revival Gross Profit Gross Margin ₹ 358.2 cr 57.8% ₹ 383.2 cr 54.1% 6.5% • Margins improvement was driven by better product mix and softer input costs EBITDA EBITDA Margin ₹ 100.1 cr 16.1% ₹ 126.9 cr 17.9% 21.1%

Primarily driven by

1) One-time Expected Credit Loss (ECL) provision for the Emerging Market Division- ₹10.48 Cr 2) Adverse operating leverage amid softer demand. Demand has started improving in Q2 Net Profit Net Margin ₹ 58.2 cr 9.3% ₹ 90.7 cr 12.5% 35.8% • Largely due to EBITDA impact, forex loss and higher finance costs from lease rentals www.marksanspharma.com Note: Net Income Margin = Net profit / Total Income (Revenue from operations + Other Income) Page 7 Financial & Other Highlights – Q1FY26 Revenue Contribution for Q1FY26: US - ₹ 327.6 cr | UK & Europe - ₹ 203.8 cr | Australia & New Zealand - ₹ 57.0 cr |RoW - ₹ 31.6 cr Research & Development (R&D) spends at ₹ 12.1 cr in Q1FY26, 2.0% of consolidated revenue Cash generated from operations at ₹ 48.7 cr Capex of ₹ 37.8 cr incurred Cash Balance of ₹ 711 cr as on 30th June 2025 Working capital cycle ~159 days for Q1FY26. During the quarter, ramped up shipments to US to front-load volumes ahead of the expected tariff implementation

Product Approvals

USFDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC) UK, Relonchem: Received Marketing Authorization for – i) Oxybutynin hydrochloride 2.5mg/5ml Oral Solution ii) Metformin Hydrochloride 500mg/5ml Oral Solution www.marksanspharma.com Page 8 Revenue by Segment and Geography FY25 Revenue by Segment Rx 25.9% Q1 FY26 Revenue by Geography US & North America ₹ 327.6 cr 31% YoY UK & Europe ₹ 203.8 cr 19% YoY 52.8% 32.9% OTC 74.1% OTC Rx Our OTC segment grew at a CAGR of 21% (from FY17 to FY25). www.marksanspharma.com 5.1% RoW - ₹ 31.6 cr 39% YoY 9.2% Australia & New Zealand ₹ 57.0 cr 13% YoY Page 9 Quarterly Financial Trends Operating Revenue (₹ cr) Gross Profit (₹ cr) & Gross Margin (%) 642 591 682 709 620 410 390 370 350 330 310 290 270 250 329 55.7% 384 384 383 59.7% 56.2% 54.1% 358 57.8% Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 Q1FY25 Q2FY25 Q3FY25 Q4FY25 Q1FY26 EBITDA (₹ cr) & EBITDA Margin (%) Net Income (₹ cr) & Net Income Margin (%) 128 21.7% 136 139 21.1% 20.4% 140 130 120 11

Total Capacity

26 bn units p.a.* Manufacturing Facility in Southport, UK • Manufactures non-sterile liquids, ointments and powder sachets • Supplies to UK, West Africa & Middle East • Spread across 7,300 sq. mt. C APACI T Y 2 bn bottles p.a. 1 bn tubes p.a. 1 bn sachets p.a. ACC RED ITATI ONS Unit 2 in Goa Acquired Manufacturing facility in Goa • Scalable capacity with a plan to double the existing Indian capacity from 8bn units per annum • Manufacturing site is spread across 47,597 sq. mt. • Plan to manufacture tablets, ointments, liquids and creams ACC RED ITATI ONS www.marksanspharma.com *Acquired facility in Goa has scalable capacity to 8bn units p.a. Page 18 R&D Capabilities R&D (₹ cr) and R&D % to sales 0.6% 0.6% 1.5% 0.7% 1.4% 2.0% 1.6% 1.6% 2.2% 2.0% 58 30 29 35 15 8 5 5 19 12 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 Q1FY26 Southport, United Kingdom Farmingdale, United States Navi Mumbai, India Goa, India R&D Centers Continued focus on R&D investments leading to a robust pipeline of new d

For more information please contact

Jitendra Sharma (CFO) Marksans Pharma Ltd. Tel: +91 22 4001-2000 jitendra@marksanspharma.com Corporate Office 11th Floor Grandeur, Off Veera Desai Road, Opp Gundecha Symphony, Andheri (W), Mumbai – 400 053, Maharashtra - India www.marksanspharma.com © 2025 Marksans Pharma Ltd., All Rights Reserved. “Marksans Pharma” and The Marksans Pharma Logo are trademarks of Marksans Pharma Limited. In addition to Company data, data from market research agencies, Stock Exchanges and industry publications has been used for this presentation. This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole on or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.